Novelix Pharmaceuticals Board of Directors

Get the latest insights into the leadership at Novelix Pharmaceuticals. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Venkateshwarlu Pulluru Whole Time Director
Mrs. Monam Kapoor Independent Director
Mr. Janardhan Das Kabra Independent Director
Mr. Gattu Gnana Prakash Independent Director

Novelix Pharmaceuticals Share price

NOVELIX

39.65

0.60 (-1.49%)
Last updated on 4 Sep, 2025 | 14:51 IST
BUYSELL
Today's High

41.90

Today's Low

39.65

52 Week Low

20.87

52 Week High

52.79

The current prices are delayed, login to your account for live prices

Novelix Pharmaceuticals FAQs

The board at Novelix Pharmaceuticals consists of experienced professionals, including Mr. Venkateshwarlu Pulluru , Mrs. Monam Kapoor , and others, overseeing the company’s strategic and corporate governance.

Directors at Novelix Pharmaceuticals are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Venkateshwarlu Pulluru is the current chairman at Novelix Pharmaceuticals.

Executive directors at Novelix Pharmaceuticals are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Novelix Pharmaceuticals adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Novelix Pharmaceuticals, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.